<p class="bodytext">The recruitment for the clinical trial of the country's first indigenously-developed Covid-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday.</p>.<p class="bodytext">This will be followed by the clinical trial of children in the age-group of 2-6 years.</p>.<p class="bodytext">The enrolment of children volunteers aged 12-18 years at the All India Institute of Medical Sciences (AIIMS) has been completed and they have been given the first dose of Covaxin.</p>.<p class="bodytext">"The recruitment process for the clinical trial of Covaxin among children in the age group of 6-12 years will begin from Tuesday," Dr Sanjay Rai, Professor at the Centre for Community Medicine at the AIIMS, told PTI.<br /><br /><strong>Read more: <a href="https://www.deccanherald.com/national/telangana-draws-flak-for-buying-32-luxury-cars-worth-crores-amid-covid-19-pandemic-report-997344.html" target="_blank">Telangana draws flak for buying 32 luxury cars worth crores amid Covid-19 pandemic: Report</a></strong></p>.<p class="bodytext">The Drugs Controller General of India (DCGI) had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on May 12.</p>.<p class="bodytext">The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years.</p>.<p class="bodytext">In the trial, the vaccine will be given by the intramuscular route in two doses on day 0 and day 28.</p>.<p class="bodytext">Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults in the country's ongoing Covid-19 vaccination drive.</p>.<p class="bodytext">The clinical trials will evaluate the safety, reactogenicity and immunogenicity of the vaccine in children.</p>.<p class="bodytext">The government recently cautioned that even though Covid-19 has not taken a serious shape among children till now, its impact can increase among them if there is a change in the virus behaviour or epidemiology dynamics and said preparations are being strengthened to deal with any such situation.</p>.<p class="bodytext">A national expert group has been formed to review Covid-19 cases in children and approach the pandemic in a renewed way to strengthen the country's preparedness, NITI Aayog Member (Health) V K Paul had told a press conference.</p>.<p class="bodytext">The group has examined signs that were not available four-five months before, he had said.</p>
<p class="bodytext">The recruitment for the clinical trial of the country's first indigenously-developed Covid-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday.</p>.<p class="bodytext">This will be followed by the clinical trial of children in the age-group of 2-6 years.</p>.<p class="bodytext">The enrolment of children volunteers aged 12-18 years at the All India Institute of Medical Sciences (AIIMS) has been completed and they have been given the first dose of Covaxin.</p>.<p class="bodytext">"The recruitment process for the clinical trial of Covaxin among children in the age group of 6-12 years will begin from Tuesday," Dr Sanjay Rai, Professor at the Centre for Community Medicine at the AIIMS, told PTI.<br /><br /><strong>Read more: <a href="https://www.deccanherald.com/national/telangana-draws-flak-for-buying-32-luxury-cars-worth-crores-amid-covid-19-pandemic-report-997344.html" target="_blank">Telangana draws flak for buying 32 luxury cars worth crores amid Covid-19 pandemic: Report</a></strong></p>.<p class="bodytext">The Drugs Controller General of India (DCGI) had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on May 12.</p>.<p class="bodytext">The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years.</p>.<p class="bodytext">In the trial, the vaccine will be given by the intramuscular route in two doses on day 0 and day 28.</p>.<p class="bodytext">Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults in the country's ongoing Covid-19 vaccination drive.</p>.<p class="bodytext">The clinical trials will evaluate the safety, reactogenicity and immunogenicity of the vaccine in children.</p>.<p class="bodytext">The government recently cautioned that even though Covid-19 has not taken a serious shape among children till now, its impact can increase among them if there is a change in the virus behaviour or epidemiology dynamics and said preparations are being strengthened to deal with any such situation.</p>.<p class="bodytext">A national expert group has been formed to review Covid-19 cases in children and approach the pandemic in a renewed way to strengthen the country's preparedness, NITI Aayog Member (Health) V K Paul had told a press conference.</p>.<p class="bodytext">The group has examined signs that were not available four-five months before, he had said.</p>